

Beyond the Guidelines: Investigator Perspectives on Current Cases, Clinical Issues and Ongoing Research in the Management of Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Data from Korde and colleagues published in *JAMA Oncology* indicated that minimal residual disease (MRD) negativity by multicolor flow cytometry or next-generation sequencing are both associated with significantly better _____.
 - a. Overall response rate
 - b. Progression-free survival (PFS)
 - c. Overall survival (OS)
2. The Phase II SIRIUS trial demonstrated that _____, an anti-CD38 monoclonal antibody, has clinically meaningful single-agent activity in patients with multiple myeloma (MM) who have received at least 3 prior lines of therapy or have disease that is refractory to both a proteasome inhibitor and an immunomodulatory agent.
 - a. Daratumumab
 - b. Pembrolizumab
 - c. Elotuzumab
 - d. Nivolumab
3. The results of the Phase III POLLUX trial evaluating lenalidomide and dexamethasone with or without daratumumab for patients with relapsed/refractory MM demonstrated a statistically significant improvement in PFS with the addition of daratumumab.
 - a. True
 - b. False
4. Results of the Phase III IFM 2009 trial evaluating early autologous stem cell transplant (ASCT) versus additional cycles of lenalidomide/bortezomib/dexamethasone (RVd) after RVd induction therapy for newly diagnosed MM demonstrated a PFS advantage with _____.
 - a. Additional cycles of RVd
 - b. Early ASCT
 - c. Neither a nor b
5. Results from the Phase III ASPIRE trial of lenalidomide and dexamethasone with or without carfilzomib for patients with relapsed MM demonstrated a statistically significant improvement in _____ with the addition of carfilzomib.
 - a. Median PFS
 - b. OS
 - c. Both a and b
6. The results of the Phase III TOURMALINE-MM1 trial of lenalidomide and dexamethasone with or without ixazomib for patients with relapsed or refractory MM failed to demonstrate a statistically significant improvement in PFS with the addition of ixazomib.
 - a. True
 - b. False
7. MYD88 L265P is a mutation found in 49 out of 54 patients with _____ that triggers IRAK-mediated activation of NF-kappaB signaling and provides molecular targets.
 - a. Waldenström macroglobulinemia
 - b. Smoldering myeloma
 - c. Neither a nor b
8. The NCCN Guidelines for the first-line treatment of symptomatic AL amyloidosis include _____.
 - a. CyBorD (cyclophosphamide/ bortezomib/dexamethasone)
 - b. High-dose melphalan with stem cell transplant
 - c. An anti-SAP antibody
 - d. Both a and b
 - e. All of the above

Beyond the Guidelines: Investigator Perspectives on Current Cases, Clinical Issues and Ongoing Research in the Management of Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. A recent meta-analysis of the use of lenalidomide maintenance therapy for patients with MM indicated superior _____ on the lenalidomide arms versus the placebo arms across all studies.
- a. PFS
 - b. Median OS
 - c. Both a and b
 - d. None of the above
10. According to the International Myeloma Working Group 2016 criteria, disease that is to be considered MRD negative requires a _____ in addition to the absence of aberrant clonal plasma in a bone marrow aspirate ruled out by an assay with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.
- a. Partial response
 - b. Very good partial response
 - c. Complete response